Single-chain fragment of humanized monoclonal antibody directed against complement component C5; designed to prevent complement-mediated inflammation and tissue injury. Prepn: M. J. Evans et al., WO 9529697; eidem, US 6355245 (1995, 2002 both to Alexion); and complement inhibition study: T. C. Thomas et al., Mol. Immunol. 33, 1389 (1996). Clinical pharmacology: J. C. K. Fitch et al., Circulation 100, 2499 (1999). Clinical studies in acute myocardial infarction: K. W. Mahaffey et al., ibid. 108, 1176 (2003), C. B. Granger et al., ibid. 1184; in coronary artery bypass graft surgery: E. D. Verrier et al., J. Am. Med. Assoc. 291, 2319 (2004). Review of development and therapeutic potential: P. A. Whiss, Curr. Opin. Investig. Drugs 3, 870-877 (2002); A. J. Fleisig, E. D. Verrier, Expert Opin. Biol. Ther. 5, 833-839 (2005).
Anti-inflammatory.
Anti-inflammatory (Biological Response Modifier)